At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
pembrolizumabdrug
Likely dose
pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates
In Brief
A Phase 2 clinical trial evaluating pembrolizumab for Acute Myeloid Leukemia. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study evaluates the effect of pembrolizumab on the duration of remission in acute myeloid leukemia. Pembrolizumab is given after complete remission is obtained in those with AML at least 60 years old who are not candidates for allogeneic stem cell transplant. The primary purpose of this study is determine if the time to relapse can be extended. Additionally, the safety and tolerability of pembrolizumab will be closely monitored.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartOct 2016
Primary CompletionJun 2020
Study CompletionDec 2020
TodayJul 2026
First PostedMar 15, 2016
Enrollment StartOct 4, 2016
Primary CompletionJun 11, 2020
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.3 years ago
Interventions
pembrolizumabdrug
200 mg IV given every three weeks